Korean J Women Health Nurs.  2021 Mar;27(1):49-57. 10.4069/kjwhn.2021.01.19.

What influences aromatase inhibitor continuation intention among breast cancer survivors?

• Seo YK
• Park J
• Park JH
• Kim S

• KMID: 2514704
• DOI: http://doi.org/10.4069/kjwhn.2021.01.19

Abstract

Purpose
Aromatase inhibitors (AIs) are widely prescribed for postmenopausal women with breast cancer and are known to cause musculoskeletal pain. This study aimed to identify factors associated with AI continuation intention among breast cancer survivors (BCS).
Methods
A cross-sectional survey was conducted on 123 BCS (stages I–III), who had been taking AIs for at least 6 weeks. Participants were recruited from a cancer center in Goyang, Korea, from September to November 2019. Descriptive statistics, Welch analysis of variance, Pearson correlation coefficients, and simple linear regression were used for the analysis.
Results
Belief in endocrine therapy was a significant predictor of AI continuation intention (β=.66, p<.001). The majority of participants (87.0%) reported experiencing musculoskeletal pain since taking AIs and the score for the worst pain severity within 24 hours was 5.08±2.80 out of 10. Musculoskeletal pain, however, was not associated with AI continuation intention. Fear of cancer recurrence (FCR) was clinically significant (≥13) for 74.0% of the respondents (mean, 17.62±7.14). Musculoskeletal pain severity and pain interference were significantly associated with FCR (r=.21, p<.05; r=.35, p<.01, respectively). Pain interference was significantly associated with belief in endocrine therapy (r=–.18, p<.05).
Conclusion
AI continuation intention can be modified by reinforcing patients’ belief in endocrine therapy. Musculoskeletal pain may have a negative effect on belief in endocrine therapy and increase FCR among BCS. Thus, awareness of musculoskeletal pain during AI therapy should be raised and further research is required to develop multidisciplinary pain management strategies and clinical guidelines to reinforce belief in endocrine therapy.

Keyword

Aromatase inhibitor; Breast cancer; Medication adherence; Musculoskeletal pain

Reference

References

1. Emanuel G, Henson KE, Broggio J, Charman J, Horgan K, Dodwell D, et al. Endocrine therapy in the years following a diagnosis of breast cancer: a proof of concept study using the primary care prescription database linked to cancer registration data. Cancer Epidemiol. 2019; 61:185–189. https://doi.org/10.1016/j.canep.2019.04.012.

2. Xing P, Dong H, Liu Q, Yao F, Xu Y, Chen B, et al. Impact of persistence on survival of patients with breast cancer treated with endocrine therapy in Northeast China: a prospective study. Oncotarget. 2017; 8(60):102499–102510. https://doi.org/10.18632/oncotarget.18454.

3. Beryl LL, Rendle KA, Halley MC, Gillespie KA, May SG, Glover J, et al. Mapping the decision-making process for adjuvant endocrine therapy for breast cancer: the role of decisional resolve. Med Decis Making. 2017; 37(1):79–90. https://doi.org/10.1177/0272989X16640488.

4. Lambert LK, Balneaves LG, Howard AF, Chia SK, Gotay CC. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors. BMC Cancer. 2018; 18(1):732. https://doi.org/10.1186/s12885-018-4644-7.

5. Corter AL, Broom R, Porter D, Harvey V, Findlay M. Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer. Psychooncology. 2018; 27(9):2096–2103. https://doi.org/10.1002/pon.4771.

6. Pakpour AH, Gellert P, Asefzadeh S, Updegraff JA, Molloy GJ, Sniehotta FF. Intention and planning predicting medication adherence following coronary artery bypass graft surgery. J Psychosom Res. 2014; 77(4):287–295. https://doi.org/10.1016/j.jpsychores.2014.07.001.

7. Chim K, Xie SX, Stricker CT, Li QS, Gross R, Farrar JT, et al. Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer. 2013; 13:401. https://doi.org/10.1186/1471-2407-13-401.

8. Lombard JM, Zdenkowski N, Wells K, Beckmore C, Reaby L, Forbes JF, et al. Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options. Support Care Cancer. 2016; 24(5):2139–2146. https://doi.org/10.1007/s00520-015-3001-5.

9. Park JY, Lee SK, Bae SY, Kim J, Kim MK, Kil WH, et al. Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors. J Korean Surg Soc. 2013; 85(5):205–211. https://doi.org/10.4174/jkss.2013.85.5.205.

10. Kim TH, Kang JW, Lee TH. Therapeutic options for aromatase inhibitor-associated arthralgia in breast cancer survivors: A systematic review of systematic reviews, evidence mapping, and network meta-analysis. Maturitas. 2018; 118:29–37. https://doi.org/10.1016/j.maturitas.2018.09.005.

11. Cahir C, Dombrowski SU, Kelly CM, Kennedy MJ, Bennett K, Sharp L. Women’s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. Support Care Cancer. 2015; 23(11):3115–3130. https://doi.org/10.1007/s00520-015-2685-x.

12. Lee JY, Min YH. Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer. BMC Womens Health. 2018; 18(1):48. https://doi.org/10.1186/s12905-018-0522-3.

13. Hall DL, Lennes IT, Pirl WF, Friedman ER, Park ER. Fear of recurrence or progression as a link between somatic symptoms and perceived stress among cancer survivors. Support Care Cancer. 2017; 25(5):1401–1407. https://doi.org/10.1007/s00520-016-3533-3.

14. Lopez C, Charles C, Rouby P, Boinon D, Laurent S, Rey A, et al. Relations between arthralgia and fear of recurrence: results of a cross-sectional study of breast cancer patients treated with adjuvant aromatase inhibitors therapy. Support Care Cancer. 2015; 23(12):3581–3588. https://doi.org/10.1007/s00520-015-2722-9.

15. Salgado TM, Davis EJ, Farris KB, Fawaz S, Batra P, Henry NL. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer. Breast Cancer Res Treat. 2017; 163(2):311–319. https://doi.org/10.1007/s10549-017-4177-9.

16. Castel LD, Hartmann KE, Mayer IA, Saville BR, Alvarez J, Boomershine CS, et al. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer. 2013; 119(13):2375–2382. https://doi.org/10.1002/cncr.28016.

17. Lee YH, Jeong IS. Factors influencing medication adherence to oral anticancer drugs. Asian Oncol Nurs. 2013; 13(4):201–209. https://doi.org/10.5388/aon.213.13.4.201.

18. Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, et al. Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer. Oncologist. 2016; 21(5):539–546. https://doi.org/10.1634/theoncologist.2015-0349.

19. Yun YH, Mendoza TR, Heo DS, Yoo T, Heo BY, Park HA, et al. Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory. Oncology. 2004; 66(6):439–444. https://doi.org/10.1159/000079497. PMID: 15452372.

20. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994; 23(2):129–138.

21. Simard S, Savard J. Screening and comorbidity of clinical levels of fear of cancer recurrence. J Cancer Surviv. 2015; 9(3):481–491. https://doi.org/10.1007/s11764-015-0424-4.

22. Shin J, Goo A, Ko H, Kim JH, Lim SU, Lee HK, Simard S, et al. Validation study for the korean version of Fear of Cancer Recurrence Inventory. J Korean Med Sci. 2017; 32(11):1792–1799. https://doi.org/10.3346/jkms.2017.32.11.1792.

23. Simard S, Savard J. Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer. 2009; 17(3):241–251. https://doi.org/10.1007/s00520-008-0444-y.

24. Kim SH. Development of an adjuvant endocrine therapy beliefs scale for breast cancer survivors [dissertation]. Seoul: Yonsei University;2019. 215.

25. Shim HY, Park M, Kim HJ, Kyung HS, Shin JY. Physical activity status by pain severity in patients with knee osteoarthritis: a nationwide study in Korea. BMC Musculoskelet Disord. 2018; 19(1):380. https://doi.org/10.1186/s12891-018-2301-6.

26. Cleeland CS. The brief pain inventory user guide. Houston (TX): MD Anderson Cancer Center;2009.

27. Heisig SR, Shedden-Mora MC, von Blanckenburg P, Rief W, Witzel I, Albert US, et al. What do women with breast cancer expect from their treatment? Correlates of negative treatment expectations about endocrine therapy. Psychooncology. 2016; 25(12):1485–1492. https://doi.org/10.1002/pon.4089.

28. Boonstra A, van Zadelhoff J, Timmer-Bonte A, Ottevanger PB, Beurskens CH, van Laarhoven HW. Arthralgia during aromatase inhibitor treatment in early breast cancer patients: prevalence, impact, and recognition by healthcare providers. Cancer Nurs. 2013; 36(1):52–59. https://doi.org/10.1097/NCC.0b013e31824a7e18.

29. de Mendoza AH, Cabling M, Dilawari A, Turner JW, Fernández N, Henderson A, et al. Providers’ perspectives on adherence to hormonal therapy in breast cancer survivors. is there a role for the Digital Health Feedback System? Health Technol (Berl). 2019; 9(2):175–184. https://doi.org/10.1007/s12553-018-0267-x.